Adopting non-animal methods in drug development
The passing of the FDA Modernization Act 2.0 is a commitment to reducing the use of animals in drug testing. The act allows researchers to use…
The passing of the FDA Modernization Act 2.0 is a commitment to reducing the use of animals in drug testing. The act allows researchers to use…
One of the key benefits of using aptamers instead of antibodies is how you store and use your reagent. Over the past 60 years the stability of oligonucleotides has…
As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…
Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…
Constraining an Optimer to a specific structure confers various benefits to the ligand that researchers can use for increased assay performance. Constrained Optimer structures Optimer binders are single-stranded oligonucleotides that can…
Small molecules, like drugs, hormones, vitamins, and pesticides, are ubiquitous in our environment and form key analytes that are routinely monitored in healthcare and drug development. Our Optimer platform…
From drug screening to critical assay reagents and as targeted therapeutics, aptamers are increasingly being employed across the discovery and development pipeline. Despite the large catalogues of antibodies, aptamers and…
DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…
As SARS-CoV-2 continues to mutate we demonstrate the performance of
In the age of the reproducibility crisis, working with affinity tools that offer the highest batch consistency is critical for the development of robust assays and reliable data. Aptamers,…